Tsapogas 1973.

Study characteristics
Methods	Allocation: random Not blind Exclusions after randomisation: nil Losses to follow‐up: nil
Participants	Country: USA Participants: 34 Age: mean 57 years Sex: Male and female Inclusion criteria: DVT confirmed by venogram duration < 5 days Exclusion criteria: diastolic BP > 120 mmHg; peptic ulceration; bleeding dysfunction; allergic condition; surgery < 7 days; recent streptococcal infection; streptokinase given < 6 months
Interventions	Treatment: titrated dose of streptokinase IV into ankle vein 100 mg hydrocortisone IV prior to therapy and daily for 5 days. Streptokinase 100,000 U/hr maintained and adjusted up to 72 hours. IV heparin for 1 week 6 to 12 hours after streptokinase Control: heparin IV into affected limb, 7000 U bolus then 1500 U/hr adjusted. Continued for 7 days after 48 hours of treatment Co‐treatment: bed rest, elevation of leg. Warfarin 2 days before end of therapy, continued for 4 weeks
Outcomes	7 days: clot lysis
Funding	Not reported
Declaration of interests	Not reported
Notes	Loco‐regional administration of streptokinase and heparin; calf vein thrombosis included, number not specified, equal in both groups. Streptokinase (Kabikinase, Sweden) was provided by AB Kabi, Stockholm, through Cutter Laboratories, Inc., Berkeley, California
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Based on a list of random numbers"
Allocation concealment (selection bias)	Unclear risk	"Arranged by using sealed envelopes"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	None